Human IL-12A / NKSF1 / p35 Protein, Fc Tag

Source : 

Human IL-12A, Fc Tag (NK1-H5252) is expressed from human 293 cells (HEK293). It contains AA Arg 23 - Ser 219 (Accession # P29459).

 

Molecule : IL-12A

 

Synonyms : IL12A,CLMF,IL-12A,NFSK,NKSF1,P35

 

Format : Powder

 

Category : Cytokines&Growth Factors

 

Accession : N/A

 

Storage : -20℃

 

Shipping condition : Powder,RT

 

Molecular Weight : 49.2 kDa

 

Characteristics :

This protein carries a human IgG1 Fc tag at the C-terminus. The protein has a calculated MW of 49.2 kDa. The protein migrates as 57-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

 

Endotoxin Level : Less than 1.0 EU per μg by the LAL method.

 

Buffer : Tris with Glycine, Arginine and NaCl, pH7.5

 

Description :

Interleukin-12 (IL12) is also known as natural killer cell stimulatory factor (NKSF), cytotoxic lymphocyte maturation factor (CLMF) , is a heterodimeric cytokine encoded by two separate genes, IL-12A (p35) and IL-12B (p40). IL12 is naturally produced by dendritic cells, macrophages and human B-lymphoblastoid cells (NC-37) in response to antigenic stimulation. IL-12 is involved in the differentiation of naive T cells into Th0 cells and plays an important role in the activities of natural killer cells and T lymphocytes.IL-12 also has anti-angiogenic activity, which means it can block the formation of new blood vessels. Interleukin-12 subunit alpha (IL12A) also known as NKSF1, CLMF1 and P35, IL12A shows significant sequence similarity to IL-6, G-CSF, and exerts biological activities only when the IL12B is co-expressed. IL12B deficient mice are resistant to the induction of experimental chronic inflammatory diseases whereas IL12A knock-out mice develop more severe forms, suggesting opposite functions of the two subunits in the outcome of chronic inflammatory diseases.

 

References :

(1) Kaliński P, et al., 1997, J. Immunol. 159 (1): 28–35.
(2) Chehimi J, et al., 1993, Eur J Immunol., 23(8):1826-30.
(3) Thierfelder WE, et al., Nature., 382(6587):171-4.